Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.

IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, Dabis F, Nash D, Gsponer T, Sungkanuparph S, McGowan C, May M, Cooper D, Chimbetete C, Wolff M, Collier A, McManus H, Davies MA, Costagliola D, Crabtree-Ramirez B, Chaiwarith R, Cescon A, Cornell M, Diero L, Phanuphak P, Sawadogo A, Ehmer J, Eholie SP, Li PC, Fox MP, Gandhi NR, González E, Lee CK, Hoffmann CJ, Kambugu A, Keiser O, Ditangco R, Prozesky H, Lampe F, Kumarasamy N, Kitahata M, Lugina E, Lyamuya R, Vonthanak S, Fink V, d'Arminio Monforte A, Luz PM, Chen YM, Minga A, Casabona J, Mwango A, Choi JY, Newell ML, Bukusi EA, Ngonyani K, Merati TP, Otieno J, Bosco MB, Phiri S, Ng OT, Anastos K, Rockstroh J, Santos I, Oka S, Somi G, Stephan C, Teira R, Wabwire D, Wandeler G, Boulle A, Reiss P, Wood R, Chi BH, Williams C, Sterne JA, Egger M.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e8-16. doi: 10.1097/QAI.0b013e3182a39979.

2.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

3.

Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries.

Koller M, Patel K, Chi BH, Wools-Kaloustian K, Dicko F, Chokephaibulkit K, Chimbetete C, Avila D, Hazra R, Ayaya S, Leroy V, Truong HK, Egger M, Davies MA; IeDEA, NISDI, PHACS and IMPAACT 219C studies.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):62-72. doi: 10.1097/QAI.0000000000000380.

4.

Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries.

Achhra AC, Phanuphak P, Amin J.

Curr Opin HIV AIDS. 2011 Jul;6(4):258-65. doi: 10.1097/COH.0b013e3283476c72. Review.

PMID:
21546834
5.

Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study.

Dragovic G, Smith CJ, Jevtovic D, Dimitrijevic B, Kusic J, Youle M, Johnson MA.

BMC Infect Dis. 2016 Mar 3;16:106. doi: 10.1186/s12879-016-1443-0.

6.

Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.

Mossdorf E, Stoeckle M, Mwaigomole EG, Chiweka E, Kibatala PL, Geubbels E, Urassa H, Abdulla S, Elzi L, Tanner M, Furrer H, Hatz C, Battegay M.

BMC Infect Dis. 2011 Apr 19;11:98. doi: 10.1186/1471-2334-11-98.

7.

A Decade of Combination Antiretroviral Treatment in Asia: The TREAT Asia HIV Observational Database Cohort.

[No authors listed]

AIDS Res Hum Retroviruses. 2016 Aug;32(8):772-81. doi: 10.1089/AID.2015.0294. Epub 2016 May 3.

8.

Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.

Kiertiburanakul S, Boettiger D, Lee MP, Omar SF, Tanuma J, Ng OT, Durier N, Phanuphak P, Ditangco R, Chaiwarith R, Kantipong P, Lee CK, Mustafa M, Saphonn V, Ratanasuwan W, Merati TP, Kumarasamy N, Wong WW, Zhang F, Pham TT, Pujari S, Choi JY, Yunihastuti E, Sungkanuparph S; TREAT Asia HIV Observational Databases (TAHOD); TREAT Asia Studies to Evaluate Resistance (TASER).

J Int AIDS Soc. 2014 Mar 14;17:18804. doi: 10.7448/IAS.17.1.18804. eCollection 2014.

9.

Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries.

Galárraga O, Wirtz VJ, Figueroa-Lara A, Santa-Ana-Tellez Y, Coulibaly I, Viisainen K, Medina-Lara A, Korenromp EL.

Pharmacoeconomics. 2011 Jul;29(7):579-99. doi: 10.2165/11586120-000000000-00000. Review.

10.

Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.

Clouse K, Pettifor A, Maskew M, Bassett J, Van Rie A, Gay C, Behets F, Sanne I, Fox MP.

AIDS. 2013 Feb 20;27(4):645-50. doi: 10.1097/QAD.0b013e32835c12f9.

11.

Frequency and predictors for late start of antiretroviral therapy in primary care clinics, Kampala, Uganda.

Sendagire I, Cobelens F, Kambugu A, Konde-Lule J, van der Loeff MS.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):e33-9. doi: 10.1097/QAI.0b013e318265aad7.

PMID:
22820807
12.

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.

antiretroviral therapy cohort collaboration (ART-CC), Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D.

AIDS. 2009 Oct 23;23(16):2199-208. doi: 10.1097/QAD.0b013e3283305a00.

13.

Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa.

Balestre E, Eholié SP, Lokossue A, Sow PS, Charurat M, Minga A, Drabo J, Dabis F, Ekouevi DK, Thiébaut R; International epidemiological Database to Evaluate AIDS (IeDEA) West Africa Collaboration.

AIDS. 2012 May 15;26(8):951-7. doi: 10.1097/QAD.0b013e3283528ad4.

14.

Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.

Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, Nachega JB, Dybul M, Hogg RS.

Ann Intern Med. 2011 Aug 16;155(4):209-16. doi: 10.7326/0003-4819-155-4-201108160-00358. Epub 2011 Jul 18.

PMID:
21768555
15.

Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.

Cingolani A, Cozzi Lepri A, Castagna A, Goletti D, De Luca A, Scarpellini P, Fanti I, Antinori A, d'Arminio Monforte A, Girardi E.

Clin Infect Dis. 2012 Mar;54(6):853-61. doi: 10.1093/cid/cir900. Epub 2011 Dec 12.

PMID:
22157323
16.

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

Rajasuriar R, Gouillou M, Spelman T, Read T, Hoy J, Law M, Cameron PU, Petoumenos K, Lewin SR.

PLoS One. 2011;6(6):e20713. doi: 10.1371/journal.pone.0020713. Epub 2011 Jun 2.

17.

CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts.

Wright ST, Carr A, Woolley I, Giles M, Hoy J, Cooper DA, Law MG; Australian HIV Observational Database.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):72-9. doi: 10.1097/QAI.0b013e318225ba62.

18.

Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study.

Dagenais GR, Gerstein HC, Zhang X, McQueen M, Lear S, Lopez-Jaramillo P, Mohan V, Mony P, Gupta R, Kutty VR, Kumar R, Rahman O, Yusoff K, Zatonska K, Oguz A, Rosengren A, Kelishadi R, Yusufali A, Diaz R, Avezum A, Lanas F, Kruger A, Peer N, Chifamba J, Iqbal R, Ismail N, Xiulin B, Jiankang L, Wenqing D, Gejie Y, Rangarajan S, Teo K, Yusuf S.

Diabetes Care. 2016 May;39(5):780-7. doi: 10.2337/dc15-2338. Epub 2016 Mar 10.

PMID:
26965719
19.

[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

Panel de expertos de GESIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Spanish.

PMID:
21388714
20.

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, Sonnerborg A, Aklillu E, Lindquist L.

PLoS One. 2015 May 12;10(5):e0122587. doi: 10.1371/journal.pone.0122587. eCollection 2015.

Supplemental Content

Support Center